Oppenheimer Maintains Outperform Rating for Pharming: Here's What You Need To Know

Oppenheimer has decided to maintain its Outperform rating of Pharming PHAR and raise its price target from $36.00 to $40.00.

Shares of Pharming are trading up 3.67% over the last 24 hours, at $12.71 per share.

A move to $40.00 would account for a 214.71% increase from the current share price.

About Pharming

Pharming Group is engaged in the development of products for the treatment of unmet medical needs. The company focuses on the development and production of human therapeutic proteins to provide life-changing solutions to patients. Its product includes Ruconest. Most of the revenue is generated from the United States.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.